Abstract | BACKGROUND:
Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis. The efficacy of chemotherapy against this disease is unknown. The purpose of this study was to determine the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea ( CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, to describe the clinical characteristics of these dogs, and to identify factors affecting prognosis. HYPOTHESIS: Our hypothesis is that CCNU has activity against canine histiocytic sarcoma and can improve survival in dogs with advanced disease. ANIMALS: Included in analysis are dogs diagnosed with histiocytic sarcoma who had gross measurable or residual microscopic disease and who received CCNU. METHODS: A multi-institutional, retrospective, single-arm cohort study was conducted. Available biopsy samples were tested with an antibody against CD18 when possible to confirm the diagnosis of histiocytic sarcoma. RESULTS: Fifty-nine dogs were treated at 8 institutions. Twenty-three tumor specimens were confirmed to be CD18 positive. Treatment with CCNU at 60 to 90 mg/m2 resulted in an overall response rate of 46% in the 56 dogs with gross measurable disease. All 3 dogs with minimal residual disease experienced tumor relapse but lived 433 days or more after starting CCNU. The median survival of all 59 dogs was 106 days. Thrombocytopenia (< 100,000 platelets/microL) and hypoalbuminemia were found to be negatively associated with prognosis and were predictive of < 1 month survival. CONCLUSIONS AND CLINICAL IMPORTANCE: Results suggest that CCNU is active against canine histiocytic sarcoma and may be useful in the treatment of dogs without negative prognostic factors.
|
Authors | Katherine A Skorupski, Craig A Clifford, Melissa C Paoloni, Ana Lara-Garcia, Lisa Barber, Michael S Kent, Amy K LeBlanc, Aarti Sabhlok, Elizabeth A Mauldin, Frances S Shofer, C Guillermo Couto, Karin U Sørenmo |
Journal | Journal of veterinary internal medicine
(J Vet Intern Med)
2007 Jan-Feb
Vol. 21
Issue 1
Pg. 121-6
ISSN: 0891-6640 [Print] United States |
PMID | 17338159
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Lomustine
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Cohort Studies
- Dog Diseases
(drug therapy)
- Dogs
- Female
- Lomustine
(therapeutic use)
- Male
- Retrospective Studies
- Sarcoma
(veterinary)
|